Stefania Chiappini, Clara Cavallotto, Alessio Mosca, Francesco Di Carlo, Tommaso Piro, Giulia Giovannetti, Arianna Pasino, Mariachiara Vicinelli, Chiara Lorenzini, Mariapia Di Paolo, Maria Pepe, Marco Di Nicola, Valerio Ricci, Mauro Pettorruso, Giovanni Martinotti
BACKGROUND: Dual disorders (DDs) involve the coexistence of a substance use disorder (SUD) with another mental illness, often from the psychotic and affective categories. They are quite common in clinical practice and present significant challenges for both diagnosis and treatment. This study explores the effectiveness of brexpiprazole, a third-generation antipsychotic, in an Italian sample of individuals diagnosed with schizophrenia spectrum disorder and a comorbid SUD. METHODS: Twenty-four patients, diagnosed according to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition ( DSM-5 ) and enrolled in several Italian hospitals, underwent a psychometric assessment at baseline (T0) and one month (T1) after starting brexpiprazole treatment administered at a mean dosage of 2 mg/day...
April 21, 2024: Pharmaceuticals